Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization

Journal of Capital Medical University ›› 2009, Vol. 30 ›› Issue (1): 37-40.

• 中西医结合专题 • Previous Articles Next Articles

Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization

Yang Wei¹, Yang Huasheng¹, He Xiujuan², Li Xiuhui¹, Qian Ying¹

1. Department of Integrated Traditional Chinese and Western Medicine, Beijing Youan Hospital, Capital Medical University;2. Department of Immunology,School of Basic Medical Science, Capital Medical University

Received:2008-11-18 Revised:1900-01-01 Online:2009-02-21 Published:2009-02-21

Abstract

Abstract: Objective To observe the joint effects of Chinese medicine Huqisan(HQS) and transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma(HCC) on survival time, quality of life and immune function. Methods Sixty-five patients with HCC were randomly divided into two groups: the treatment group with HQS and TACE, and the control group with Huaier Keli. After the treatment for 24 weeks, the differences in peripheral T-lymphocyte subsets, quality of life(KPS), survival time and clinical efficacy of the overall syndrome were analyzed. Results The treatment group was better than the control group in terms of peripheral blood T-lymphocyte subsets, the quality of life(KPS), survival time and clinical efficacy of the overall syndrome. Conclusion The treatment of HQS and TACE for HCC may improve the overall efficacy and the quality of life, survival time and cell immune function of patients.

Key words: hepatocellular carcinoma, Huqisan, transeatheter arterial chemoembolization, immune function, Huaierkeli

CLC Number:

R 4/78

Yang Wei;Yang Huasheng;He Xiujuan;Li Xiuhui;Qian Ying. Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization[J]. Journal of Capital Medical University, 2009, 30(1): 37-40.

[1]	Yin Xue, Yu Minghang, Wang Xi, Chen Jinglong. Progresses on the mutation of SWI/SNF complex and its impact on immune checkpoint inhibitor therapy response in hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 768-774.
[2]	Wan Yan, Liu Fang, Guo Shan, Wu Jian. Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 811-820.
[3]	Tan Yubo, Suboyinuer Tuerhong, Huang Jing, Zhang Tingting, Liu Junjie, Shaya Mahati. The mechanism of miR-150 targeted regulation of IGF2BP2 on the malignant phenotype of liver cancer [J]. Journal of Capital Medical University, 2023, 44(5): 762-767.
[4]	An Songlin, Ma Ling, Zhao Yue, Li Yan. Effects of major facilitator superfamily domain containing 2A on the cell proliferation, apoptosis and invasion of human hepatocellular carcinoma [J]. Journal of Capital Medical University, 2021, 42(6): 1000-1006.
[5]	Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients [J]. Journal of Capital Medical University, 2019, 40(6): 911-915.
[6]	Li Muchan, Xu Chunjun, Wang Yutao, Wang Cong. Clinical study on improving the quality of life in patients with early and middle stages hepatocellular carcinoma [J]. Journal of Capital Medical University, 2019, 40(3): 352-357.
[7]	Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients [J]. Journal of Capital Medical University, 2019, 40(3): 443-448.
[8]	Shen Yanjun, Chen Jinglong, Che Juanjuan, Wang Jing, Cao Bangwei. Occurrence and prognosis value of Snail and Claudin-3 expression in hepatocelluar carcinoma [J]. Journal of Capital Medical University, 2018, 39(3): 393-397.
[9]	Bai Jing, Zhang Lijun, Zhan Yutao, Guo Duo, Liu Xiangyi. Chemiluminescence immunoassay for Golgi protein 73 in human serum and its clinical application [J]. Journal of Capital Medical University, 2017, 38(4): 566-571.
[10]	Zhang Qi, Li Hongjun, Li Yunfang, Zhang Yanyan, Yuan Xingxing, Chang Jing. MR enhancement features of multistep hepatocarcinogenesis in HBV-related cirrhotic livers: correlation with GPC-3 and CD34 [J]. Journal of Capital Medical University, 2016, 37(5): 672-679.
[11]	Zhang Yanyan, Li Hongjun. MR imaging research situation of HBV related multistep hepatocarcinogenesis and the latest progress [J]. Journal of Capital Medical University, 2015, 36(4): 659-662.
[12]	LI Yunfang, LI Hongjun, ZHAO Dawei. Differential diagnostic value of two dimensional multi-breath-hold susceptibility weighted imaging for hepatocellular carcinoma and hepatic hemangioma [J]. Journal of Capital Medical University, 2013, 34(3): 358-363.
[13]	MENG Qian;ZHAO Xu-hong;ZHAO Jin;LEI Ting;ZHANG Man. Detecting the expression of serum zincα -2-glycoprotein in patients with various digestive system carcinoma and its clinical significance [J]. Journal of Capital Medical University, 2012, 33(5): 665-668.
[14]	ZHANG Shi-jie;LANG Zhen-wei;WANG Xin-xin;LV Fu-dong. Value of combined application of glypican-3 and cytokeratin-19 in diagnosis and differential diagnosis of hepatocellular carcinoma [J]. Journal of Capital Medical University, 2011, 32(5): 653-657.
[15]	ZHANG Shi-jie;LANG Zhen-wei;WANG Xin-xin;Lü Fu-dong. Specificity and sensitivity and expression of glypican-3 in hepatocellular carcinoma [J]. Journal of Capital Medical University, 2011, 32(4): 545-548.

Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments